These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11785478)

  • 1. Rescue regimens: the value of PI boosting.
    Segal-Maurer S; Schütz M
    Posit Aware; 2001; 12(6):35-7. PubMed ID: 11785478
    [No Abstract]   [Full Text] [Related]  

  • 2. Rescue regimens: the value of protease-inhibitor boosting.
    Segal-Maurer S; Schütz M
    Body Posit; 2001 Sep; 14(9):11-3. PubMed ID: 11693112
    [No Abstract]   [Full Text] [Related]  

  • 3. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 4. Protease inhibitors: opium of the masses?
    Martinez LJ
    Res Initiat Treat Action; 2000 Sep; 6(3):7-11. PubMed ID: 11708167
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV resistance: the new enemy.
    Colvin R
    Common Factor; 1997 Nov; (No 11):6-7. PubMed ID: 11364845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient adherence, not viral load now most important in HIV therapy.
    Rep Med Guidel Outcomes Res; 2000 Feb; 11(3):6-7. PubMed ID: 11768406
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
    Müller AD; Myer L; Jaspan H
    Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption.
    Barreiro P; de Mendoza C; González-Lahoz J; Soriano V
    Clin Infect Dis; 2005 Sep; 41(6):897-900. PubMed ID: 16107992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Another take on when to start and how to succeed.
    Friedland GH
    AIDS Clin Care; 2001 Sep; 13(9):82. PubMed ID: 11547600
    [No Abstract]   [Full Text] [Related]  

  • 11. Substitution for protease inhibitors in HIV therapy.
    Mikhail E
    N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14689602
    [No Abstract]   [Full Text] [Related]  

  • 12. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New versions of antiretroviral guidelines contain some important changes.
    Murphy MJ
    Fac Notes (New Orleans La); 1999; 11(4):1-3. PubMed ID: 11810843
    [No Abstract]   [Full Text] [Related]  

  • 14. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy for HIV disease.
    Frascino RJ
    West J Med; 1997 Nov; 167(5):346-7. PubMed ID: 9392987
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiretroviral rounds. Putting resistance to work.
    Daar ES; Elion R
    AIDS Clin Care; 2004 Jul; 16(7):56, 60. PubMed ID: 15300926
    [No Abstract]   [Full Text] [Related]  

  • 17. How HIV drugs work 101.
    Pietrandoni G
    Posit Aware; 2001; 12(5):26-7. PubMed ID: 11688481
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
    Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
    HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
    Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
    Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for HIV Infection.
    Treat Guidel Med Lett; 2004 Jan; 2(17):1-8. PubMed ID: 15529108
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.